Clinical analysis of 12 cases of ovarian neuroendocrine carcinoma

Table 1 Clinical characteristics of 12 cases with neuroendocrine carcinoma of the ovary

Case	Age (yr)	Symptom	CA-125 (U/mL)	Size (cm)	Location	Diagnosis	Stage
1	28	Mass	91.4	12	Right	SCCO	IA
2	62	Pain	38.63	14	Left	LCNEC	IA
3	29	Pain	46.4	8	Right	SCCO	IA
4	37	Mass	42.13	8	Right	SCCO	IA
5	20	Pain	401.2	20	Bilateral	SCCO	IC
6	54	Bloating	170.6	5	Bilateral	LCNEC	IIIB
7	26	Pain	150.7	5	Bilateral	SCCO	IIIC
8	31	Mass	61.25	10	Left	SCCO	IIIC
9	32	Pain	146.6	10	Bilateral	SCCO	IIIC
10	46	Mass	191	13	Bilateral	LCNEC	IIIC
11	58	Bleeding	14.5	4	Bilateral	SCCO	IIIC
12	62	Bleeding	166.5	15	Bilateral	SCCO	IVB

CA-125: Antigen 125; SCCO: Small cell carcinoma of the ovary; LCNEC: Large cell neuroendocrine carcinoma.

Table 2 The follow-up time for the 12 cases

Case	Operation	Chemotherapy	Recurrence	PFS/month	Survival state	Follow-up/month
1	BSO/TAH/OM/LN	EP6	No	34	NED	34
2	BSO/TAH/OM/LN	TC6	No	37	NED	37
3	USO	EP7	Yes, brain	9	DOD	10
4	BSO/TAH/OM/LN	EP6	Yes, liver	13	AWD	13
5	BSO/OM /LN	EP6	Yes, bones	17	AWD	25
6	NACT+BSO/TAH/OM/LN	TC8	Yes, pelvic	13	AWD	15
7	OM/PB	TC3	Yes, pelvic	3	DOD	10
8	BSO/TAH/OM/LN	EP6	No	15	NED	26
9	BSO/TAH/OM/LN	TP6	Yes, lymph	6	AWD	17
10	BSO/TAH/OM/LN	TP6 +PARPi	Yes, liver	9	AWD	22
11	BSO/TAH/OM/LN	TC6+ Radiotherapy	No	49	NED	49
12	-	EP6	Yes, pelvic	6	DOD	9

EP: Etoposide/Cisplatin; TC: Paclitaxel/Carboplatin; TP: Paclitaxel/Cisplatin; DOD: Dead of disease; AWD: Alive with disease; NED: No evidence of disease; Om: Omentectomy; USO: Unilateral salpingo-oophorectomy; BSO: Bilateral salpingo-oophorectomy; LN: Lymph node dissection; PB: Peritoneal biopsy; NACT: Neoadjuvant chemotherapy.